- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06843447
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Wieloośrodkowe, wieloośrodkowe badanie fazy 1B/2 w celu oceny bezpieczeństwa i skuteczności deruxtecan Raludotatug z innymi środkami badawczą przeciwnowotworowymi lub bez środków badawczych u uczestników z wysokiej jakości surowiczno jajnik
Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes.
Standard treatment (usual treatment) for people with high-grade serous ovarian cancer may include:
- Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing
- Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread
Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.
Przegląd badań
Status
Warunki
Szczegółowy opis
This study has 2 parts: Part 1 is a dose escalation phase of R-DXd. Part 2 is the expansion phase and will use the Recommended Phase 2 Dose (RP2D) of R-DXd determined in Part 1.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Toll Free Number
- Numer telefonu: 1-888-577-8839
- E-mail: Trialsites@msd.com
Lokalizacje studiów
-
-
Victoria
-
St Albans, Victoria, Australia, 3021
- Rekrutacyjny
- Western Health-Sunshine & Footscray Hospitals ( Site 1002)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +61402775432
-
-
-
-
-
Barcelona, Hiszpania, 08035
- Rekrutacyjny
- Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +349325434528607
-
Madrid, Hiszpania, 28041
- Rekrutacyjny
- Hospital Universitario 12 de Octubre ( Site 0304)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +34913908626
-
Madrid, Hiszpania, 28040
- Rekrutacyjny
- Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 34915504800 x2805
-
Málaga, Hiszpania, 29010
- Rekrutacyjny
- Hospital Universitario Virgen de la Victoria ( Site 0306)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +34951032508
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Hiszpania, 08908
- Rekrutacyjny
- Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +34932607744
-
-
Madrid
-
Majadhonda, Madrid, Hiszpania, 28222
- Rekrutacyjny
- HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +34 911917358
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Hiszpania, 28027
- Rekrutacyjny
- Clinica Universidad de Navarra ( Site 0301)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +349135319207513
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Hiszpania, 46014
- Rekrutacyjny
- Hospital General Universitario de Valencia ( Site 0305)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +34 963187527
-
-
-
-
-
Haifa, Izrael, 3109601
- Rekrutacyjny
- Rambam Health Care Campus ( Site 0202)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 972-4-7776234
-
Jerusalem, Izrael, 9103102
- Rekrutacyjny
- Shaare Zedek Medical Center ( Site 0201)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +972-(0)2-6555424
-
Petah Tikva, Izrael, 4941492
- Rekrutacyjny
- Rabin Medical Center ( Site 0203)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +97239378076
-
Ramat Gan, Izrael, 5265601
- Rekrutacyjny
- Sheba Medical Center ( Site 0200)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 972-3-5304498
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 2M9
- Rekrutacyjny
- Princess Margaret Cancer Centre ( Site 0101)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 416-946-2818
-
-
Quebec
-
Montreal, Quebec, Kanada, H4A 3J1
- Rekrutacyjny
- McGill University Health Centre ( Site 0100)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 514-934-1934x31975
-
Montreal, Quebec, Kanada, H2X 0A9
- Rekrutacyjny
- Centre Hospitalier de l'Université de Montréal ( Site 0102)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 514-890-8000
-
-
-
-
-
Seoul, Korea Południowa, 03080
- Rekrutacyjny
- Seoul National University Hospital ( Site 2000)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +82220723511
-
Seoul, Korea Południowa, 03722
- Rekrutacyjny
- Severance Hospital, Yonsei University Health System ( Site 2002)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +82222282230
-
Seoul, Korea Południowa, 05505
- Rekrutacyjny
- Asan Medical Center ( Site 2003)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +82230103646
-
Seoul, Korea Południowa, 06351
- Rekrutacyjny
- Samsung Medical Center ( Site 2001)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 82234101382
-
-
Kyonggi-do
-
Goyang-si, Kyonggi-do, Korea Południowa, 10408
- Rekrutacyjny
- National Cancer Center ( Site 2004)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 82319201760
-
-
-
-
Connecticut
-
New Haven, Connecticut, Stany Zjednoczone, 06510
- Rekrutacyjny
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 203-785-2404
-
-
Kentucky
-
Louisville, Kentucky, Stany Zjednoczone, 40202
- Rekrutacyjny
- The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 502-562-3429
-
-
Louisiana
-
Shreveport, Louisiana, Stany Zjednoczone, 71103
- Rekrutacyjny
- TRIALS 365 ( Site 0020)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 318-408-1198
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02215
- Rekrutacyjny
- Dana-Farber Cancer Institute ( Site 0015)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 877-338-7425
-
-
New York
-
New York, New York, Stany Zjednoczone, 10065
- Rekrutacyjny
- Memorial Sloan Kettering Cancer Center ( Site 0003)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 212-639-2000
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
- Rekrutacyjny
- OU Health University of Oklahoma Medical Center ( Site 7000)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 405-271-1112
-
-
Texas
-
Fort Worth, Texas, Stany Zjednoczone, 76104
- Rekrutacyjny
- Texas Oncology - DFW ( Site 8000)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 615-329-7430
-
Houston, Texas, Stany Zjednoczone, 77030
- Zakończony
- Houston Methodist Hospital ( Site 0010)
-
-
Utah
-
West Valley City, Utah, Stany Zjednoczone, 84119
- Rekrutacyjny
- START Mountain Region ( Site 0008)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 801-907-4750
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22908
- Rekrutacyjny
- University of Virginia Health System ( Site 0011)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 434-924-9333
-
-
-
-
-
Sankt Gallen, Szwajcaria, 9000
- Rekrutacyjny
- HOCH Health Ostschweiz ( Site 0801)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +41714941111
-
-
Canton of Basel-City
-
Basel, Canton of Basel-City, Szwajcaria, 4031
- Rekrutacyjny
- University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 0802)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +41613284214
-
-
Canton of Vaud
-
Lausanne, Canton of Vaud, Szwajcaria, 1011
- Rekrutacyjny
- CHUV (centre hospitalier universitaire vaudois) ( Site 0800)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +41795567362
-
-
-
-
-
Taipei, Tajwan, 100225
- Rekrutacyjny
- National Taiwan University Hospital ( Site 3001)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +886223123456
-
Taoyuan, Tajwan, 33305
- Rekrutacyjny
- Chang Gung Medical Foundation-Linkou Branch ( Site 3002)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +88633281200
-
-
-
-
-
Manchester, Zjednoczone Królestwo, M20 4BX
- Rekrutacyjny
- The Christie NHS Foundation Trust ( Site 0405)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +441619187689
-
-
East Sussex
-
Brighton, East Sussex, Zjednoczone Królestwo, BN2 1ES
- Rekrutacyjny
- University Hospitals Sussex NHS Foundation Trust ( Site 0404)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +44 01273 696 955
-
-
England
-
Fulham, England, Zjednoczone Królestwo, SW3 6JJ
- Rekrutacyjny
- Royal Marsden Hospital ( Site 0402)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +442078118084
-
Sutton, England, Zjednoczone Królestwo, SM2 5PT
- Rekrutacyjny
- The Royal Marsden NHS Foundation Trust. ( Site 0403)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +442078118084
-
-
London, City of
-
London, London, City of, Zjednoczone Królestwo, E1 1RD
- Rekrutacyjny
- Barts Health NHS Trust ( Site 0401)
-
Kontakt:
- Study Coordinator
- Numer telefonu: 020 7377 7000
-
London, London, City of, Zjednoczone Królestwo, SE1 3SS
- Rekrutacyjny
- Guy s & St Thomas NHS Foundation Trust ( Site 0400)
-
Kontakt:
- Study Coordinator
- Numer telefonu: +44 020 7188 7188
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Has pathologically documented diagnosis of high-grade serous or high-grade endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
- Participants in Part 1 cohorts and Part 2 Cohort A-2 Arms 1, 2, and 3, Cohort B-2, and Cohort C-2 Arm 3: Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1
- Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
- Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression <6 months (<180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen
- Participants in Cohort B-1, Cohort B-2, Cohort C-2 Arm 3, Cohort E-1 and if administering bevacizumab is planned in Cohort D or Cohort A-2 Arms 1, 2, or 3: Is a candidate for bevacizumab treatment
- Has provided tumor tissue for biomarker research (all cohorts)
- Has an Eastern Cooperative Oncology Group performance status of 0 to 1
- Participants in Cohort C-1, Cohort C-2 Arm 3, Cohort D, and Cohort E-1: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with poly-ADP ribose polymerase inhibitor (PARPi) in the first-line setting
- Participants in Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
- Participants in Cohort C-2 Arms 1 and 2: Has a new, histologically confirmed diagnosis of International Federation of Gynecology and Obstetrics Stage III or Stage IV epithelial ovarian cancer (high-grade serous or high-grade endometrioid), fallopian tube cancer, or primary peritoneal cancer that is non-homologous recombination deficiency-positive
- Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, PARPi first-line maintenance treatment for non- homologous recombination deficiency (HRD)-positive disease is not the preferred option for the participant
- Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, bevacizumab treatment for non-HRD-positive disease is not the preferred option for the participant
Exclusion Criteria:
- Has any of the following within 6 months before allocation/randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event
- Has uncontrolled or significant cardiovascular disease
- Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy
- Has ≥Grade 2 peripheral neuropathy
- Has received prior treatment with cadherin-6-targeted agents
- Has received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation
- Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring corticosteroids
- Receives chronic steroid treatment
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active CNS metastases and/or carcinomatous meningitis
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening
- Has active infection requiring systemic therapy
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)
Participants receive escalating doses of intravenous (IV) raludotatug deruxtecan (R-DXd) in combination with carboplatin at Dose 1. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive raludotatug deruxtecan until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. |
|
Eksperymentalny: Cohort A-1 Arm 2 (R-DXd + Paclitaxel)
Participants receive escalating doses of IV R-DXd in combination with paclitaxel. Participants can receive up to a maximum of six 3-week cycles of paclitaxel (approximately 4 months) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. |
|
Eksperymentalny: Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)
Participants receive escalating doses of intravenous (IV) R-DXd in combination with carboplatin at Dose 2. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. |
|
Eksperymentalny: Cohort B-1 (R-DXd + Bevacizumab)
Participants receive escalating doses of IV R-DXd in combination with bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
|
|
Eksperymentalny: Cohort B-2 (R-DXd RP2D + Bevacizumab)
Participants with platinum-resistant recurrent ovarian cancer (PRROC) receive recommended Phase 2 dose (RP2D) of IV R-DXd in combination with bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
|
|
Eksperymentalny: Cohort C-1 (R-DXd + Pembrolizumab)
Participants receive escalating doses of IV R-DXd in combination with pembrolizumab. Participants can receive up to a maximum of thirty-five 3-week cycles of pembrolizumab (approximately 2 years) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
|
Eksperymentalny: Cohort D (R-DXd +/- Bevacizumab)
Participants with platinum-sensitive recurrent ovarian cancer (PSROC) receive IV R-DXd in combination with or without bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
|
|
Eksperymentalny: Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)
Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of carboplatin with or without bevacizumab, until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
|
|
Eksperymentalny: Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)
Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of paclitaxel with or without bevacizumab, until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
|
|
Aktywny komparator: Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)
Participants with PSROC will receive one of 3 regimens of investigator's choice of platinum-based doublet chemotherapy with or without bevacizumab. Platinum-based doublet chemotherapy will be administered for maximum of 8 cycles. Bevacizumab can be administered until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
IV injection on days 1 and 8 of each 3-week Cycle IV injection administered on Day 1 of each 4-week cycle
Inne nazwy:
|
|
Eksperymentalny: Cohort E-1 (R-DXd + MK-2010)
Participants receive escalating doses of IV R-DXd in combination with MK-2010. Participants can receive up to a maximum of thirty-five 3-week cycles of MK-2010 (approximately 2 years) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle |
|
Eksperymentalny: Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)
Participants will receive carboplatin (Dose 1 or Dose 2), paclitaxel (five 3-week cycles), and pembrolizumab during the induction phase. During the maintenance phase, participants will receive RP2D of IV R-DXd (up to 2 years; participants with PR or SD at 2 years may continue until disease progression) in combination with pembrolizumab (up to thirty-five 3-week cycles). |
IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
|
Eksperymentalny: Cohort C-2 Arm 2 (Carboplatin + Paclitaxel)
Participants will receive carboplatin (Dose 1 or Dose 2) and paclitaxel (seven 3-week cycles), followed by standard of care observation. |
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. |
|
Eksperymentalny: Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)
Participants with PSROC will receive RP2D of R-DXd in combination with pembrolizumab (up to thirty-five 3-week cycles) and bevacizumab until progressive disease. |
IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
IV infusion on Day 1 of every 3-week cycle.
Inne nazwy:
IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)
Ramy czasowe: Up to 21 days
|
DLTs are defined as toxicities during the DLT evaluation period that are assessed by the investigator to be possibly, probably, or definitely related to study treatment and include: Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia lasting ≥7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding; Grade 4 lymphocytopenia lasting ≥14 days; Grade 4 anemia of any duration; any other Grade 4 hematologic toxicity lasting ≥7 days; febrile neutropenia Grade 3 or Grade 4 meeting pre-specifications; pre-specified hepatic organ toxicities; all Grade 3 or higher other nonhematologic toxicities except those pre-specified; other pre-specified nonhematologic toxicities; any delay in treatment with the planned dose of ≥21 days or discontinuation of treatment due to a toxicity during the DLT evaluation period, or Grade 5 toxicity. The number of participants with DLTs will be reported. |
Up to 21 days
|
|
Part 1: Number of Participants with One or More Adverse Events (AEs)
Ramy czasowe: Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs will be reported. |
Up to approximately 3 years
|
|
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Ramy czasowe: Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
|
Part 2: Objective Response Rate (ORR)
Ramy czasowe: Up to approximately 3 years
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2
Ramy czasowe: Up to approximately 3 years
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented. |
Up to approximately 3 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Part 1: Objective Response Rate (ORR)
Ramy czasowe: Up to approximately 3 years
|
ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST 1.1). ORR will be assessed by blinded independent central review (BICR). |
Up to approximately 3 years
|
|
Part 2: Duration of Response (DOR)
Ramy czasowe: Up to approximately 3 years
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: PFS - Cohort A-2 Arm 2 and Arm 3
Ramy czasowe: Up to approximately 3 years
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: Overall Survival (OS)
Ramy czasowe: Up to approximately 5 years
|
OS is defined as the time from the first dose of study treatment to death due to any cause. |
Up to approximately 5 years
|
|
Part 2: Number of Participants with One or More AEs
Ramy czasowe: Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
|
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Ramy czasowe: Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Dyrektor Studium: Medical Director, Merck Sharp & Dohme LLC
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Aminokwasy, peptydy i białka
- Białka
- Organiczne chemikalia
- Związki heterocykliczne, 1-ring
- Związki heterocykliczne
- Węglowodory
- Cykloparafiny
- Węglowodory, Alicyklic
- Węglowodory, cykliczne
- Terpeny
- Przeciwciała, monoklonalne, humanizowane
- Przeciwciała, monoklonalne
- Przeciwciała
- Immunoglobuliny
- Immunoproteiny
- Białka krwi
- Globuliny w surowicy
- Globuliny
- Kompleksy koordynacyjne
- Taksoidy
- Cyklodekan
- Diterpenes
- Deoksycytydyna
- Cytydyna
- Nukleozydy pirymidynowe
- Pirymidyn
- Bewacyzumab
- Gemcytabina
- Karboplatyna
- Paklitaksel
- pembrolizumab
- liposomalna doksorubicyna
- 1-Dodecylopyridoxal
Inne numery identyfikacyjne badania
- 5909-003
- MK-5909-003 (Inny identyfikator: MSD)
- U1111-1308-2821 (Identyfikator rejestru: UTN)
- 2024-514674-47-00 (Identyfikator rejestru: EU CT)
- REJOICE-Ovarian02 (Inny identyfikator: MSD)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .